Brainstorm Cell Therapeutics Inc (BCLI)
0.532
-0.01
(-2.39%)
USD |
NASDAQ |
Apr 25, 16:00
0.5374
+0.01
(+1.02%)
After-Hours: 20:00
Brainstorm Cell Therapeutics Cash from Financing (TTM): 18.98M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 18.98M |
| September 30, 2023 | 15.86M |
| June 30, 2023 | 8.767M |
| March 31, 2023 | 3.468M |
| December 31, 2022 | 0.238M |
| September 30, 2022 | -0.034M |
| June 30, 2022 | -0.14M |
| March 31, 2022 | -0.14M |
| December 31, 2021 | 6.969M |
| September 30, 2021 | 27.94M |
| June 30, 2021 | 47.68M |
| March 31, 2021 | 55.09M |
| December 31, 2020 | 76.94M |
| September 30, 2020 | 58.06M |
| June 30, 2020 | 41.59M |
| March 31, 2020 | 34.18M |
| December 31, 2019 | 5.225M |
| September 30, 2019 | 3.161M |
| June 30, 2019 | 0.051M |
| March 31, 2019 | 12.04M |
| December 31, 2018 | 12.06M |
| September 30, 2018 | 12.27M |
| June 30, 2018 | 12.30M |
| March 31, 2018 | 0.339M |
| December 31, 2017 | 0.314M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.105M |
| June 30, 2017 | 0.03M |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.111M |
| June 30, 2016 | 0.111M |
| March 31, 2016 | 0.123M |
| December 31, 2015 | 14.87M |
| September 30, 2015 | 14.80M |
| June 30, 2015 | 15.17M |
| March 31, 2015 | 24.43M |
| December 31, 2014 | 9.685M |
| September 30, 2014 | 9.64M |
| June 30, 2014 | 12.60M |
| March 31, 2014 | 3.334M |
| December 31, 2013 | 3.584M |
| September 30, 2013 | 3.578M |
| June 30, 2013 | 5.28M |
| March 31, 2013 | 5.399M |
| December 31, 2012 | 5.169M |
| September 30, 2012 | 4.263M |
| June 30, 2012 | 0.557M |
| March 31, 2012 | 0.475M |
| December 31, 2011 | 4.117M |
| September 30, 2011 | 4.915M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.14M
Minimum
Mar 2022
76.94M
Maximum
Dec 2020
21.26M
Average
8.767M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
| NovaBay Pharmaceuticals Inc | 1.91M |
| Palatin Technologies Inc | 5.553M |
| iBio Inc | 10.68M |
| Theriva Biologics Inc | 0.625M |
| Oragenics Inc | 0.2839M |